by Stefan Ravello | May 11, 2026 | Hematology-Oncology, Multiple Myeloma
Multiple myeloma (MM) is a malignant plasma cell disorder and the second most common blood cancer in the United States (U.S.) Survival has improved markedly with modern therapies – the 5-year survival rate has more than doubled in recent decades – yet myeloma remains...
by Stefan Ravello | Feb 11, 2026 | Neurology
The recent development and approval of blood-based biomarker tests (BBMs) for detecting neuropathologic changes associated with Alzheimer’s disease (AD) can enhance the care of patients by facilitating earlier diagnosis in both primary care and specialty settings....
by Stefan Ravello | Feb 11, 2026 | Psychiatry
In the United States (U.S.), major depressive disorder (MDD) is a prevalent and debilitating illness with a high burden of disease. Effective management of depression is therefore critical, yet achieving and sustaining remission remains challenging in practice. While...
by Stefan Ravello | Feb 11, 2026 | Nephrology
Complement-mediated kidney diseases (CMKDs), including C3 glomerulopathy, atypical hemolytic uremic syndrome, IgA nephropathy, and membranous nephropathy, are rare and complex disorders driven by dysregulation of the complement system and associated with poor renal...
by Stefan Ravello | Feb 11, 2026 | Oncology
This curriculum is designed to equip multidisciplinary clinicians with the up-to-date knowledge and skills needed to accurately identify, interpret, and apply dMMR/MSI-H biomarker testing in the management of early and locally advanced colorectal cancer. Through an...
